CD30 CAR T 细胞治疗后，多次复发肠病相关 T 细胞淋巴瘤达到长期缓解。
Long-term remission in multiply relapsed enteropathy-associated T-cell lymphoma following CD30 CAR T-cell therapy.
机构信息
University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; and.
Levine Cancer Institute, Atrium Health, Charlotte, NC.
出版信息
Blood Adv. 2020 Dec 8;4(23):5925-5928. doi: 10.1182/bloodadvances.2020003218.
Abstract
CD30 CAR T-cell therapy promoted a prolonged remission in a patient with multiply relapsed EATL.
摘要
CD30 CAR T 细胞疗法使 1 例复发性 EATL 患者获得持久缓解。
相似文献
1
Long-term remission in multiply relapsed enteropathy-associated T-cell lymphoma following CD30 CAR T-cell therapy.CD30 CAR T 细胞治疗后，多次复发肠病相关 T 细胞淋巴瘤达到长期缓解。
Blood Adv. 2020 Dec 8;4(23):5925-5928. doi: 10.1182/bloodadvances.2020003218.
2
Anti-CD30 chimeric antigen receptor T cell therapy for relapsed/refractory CD30 lymphoma patients.抗CD30嵌合抗原受体T细胞疗法用于复发/难治性CD30淋巴瘤患者。
Blood Cancer J. 2020 Jan 23;10(1):8. doi: 10.1038/s41408-020-0274-9.
3
Challenges of driving CD30-directed CAR-T cells to the clinic.将 CD30 导向 CAR-T 细胞推向临床应用所面临的挑战。
BMC Cancer. 2019 Mar 6;19(1):203. doi: 10.1186/s12885-019-5415-9.
4
Blocking CD30 on T Cells by a Dual Specific CAR for CD30 and Colon Cancer Antigens Improves the CAR T Cell Response against CD30 Tumors.双特异性 CAR 通过靶向 CD30 和结直肠癌抗原阻断 T 细胞上的 CD30 可改善 CAR T 细胞对 CD30 肿瘤的反应。
Mol Ther. 2019 Oct 2;27(10):1825-1835. doi: 10.1016/j.ymthe.2019.06.007. Epub 2019 Jun 19.
5
Chimeric antigen receptor T-cell therapy targeting CD30 in Hodgkin lymphoma.靶向霍奇金淋巴瘤中CD30的嵌合抗原受体T细胞疗法。
Clin Adv Hematol Oncol. 2021 Jan;19(1):24-26.
6
A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma.一大步的迈进：嵌合抗原受体 T 细胞疗法治疗淋巴瘤。
Front Med. 2020 Dec;14(6):711-725. doi: 10.1007/s11684-020-0808-3. Epub 2020 Dec 1.
7
CD30-Redirected Chimeric Antigen Receptor T Cells Target CD30 and CD30 Embryonal Carcinoma via Antigen-Dependent and Fas/FasL Interactions.CD30 重定向嵌合抗原受体 T 细胞通过抗原依赖性和 Fas/FasL 相互作用靶向 CD30 和 CD30 胚胎性癌。
Cancer Immunol Res. 2018 Oct;6(10):1274-1287. doi: 10.1158/2326-6066.CIR-18-0065. Epub 2018 Aug 7.
8
CD30 expression is frequently decreased in relapsed classic Hodgkin lymphoma after anti-CD30 CAR T-cell therapy.CD30 表达在抗 CD30 CAR T 细胞治疗后复发的经典霍奇金淋巴瘤中经常降低。
Histopathology. 2023 Jul;83(1):143-148. doi: 10.1111/his.14910. Epub 2023 Mar 30.
9
A new immunotherapy strategy targeted CD30 in peripheral T-cell lymphomas: CAR-modified T-cell therapy based on CD30 mAb.一种针对外周 T 细胞淋巴瘤的新型免疫治疗策略：基于 CD30 mAb 的嵌合抗原受体修饰 T 细胞疗法。
Cancer Gene Ther. 2022 Feb;29(2):167-177. doi: 10.1038/s41417-021-00295-8. Epub 2021 Jan 29.
10
CD28.OX40 co-stimulatory combination is associated with long in vivo persistence and high activity of CAR.CD30 T-cells.CD28.OX40 共刺激组合与 CAR.CD30 T 细胞的体内长期持久性和高活性相关。
Haematologica. 2021 Apr 1;106(4):987-999. doi: 10.3324/haematol.2019.231183.
引用本文的文献
1
Genetically modified and unmodified cellular approaches to enhance graft versus leukemia effect, without increasing graft versus host disease: the use of allogeneic cytokine-induced killer cells.利用同种异体细胞因子诱导的杀伤细胞增强移植物抗白血病效应而不增加移植物抗宿主病：基因修饰和未修饰的细胞方法。
Front Immunol. 2024 Oct 24;15:1459175. doi: 10.3389/fimmu.2024.1459175. eCollection 2024.
2
Monomorphic epitheliotropic intestinal T-cell lymphoma: report of four cases and literature review.单一表型上皮样肠道 T 细胞淋巴瘤：4 例报告及文献复习。
J Int Med Res. 2024 Aug;52(8):3000605241271756. doi: 10.1177/03000605241271756.
3
Advances in CAR-T-cell therapy in T-cell malignancies.嵌合抗原受体 T 细胞疗法在 T 细胞恶性肿瘤中的进展。
J Hematol Oncol. 2024 Jun 24;17(1):49. doi: 10.1186/s13045-024-01568-z.
4
Novel and multiple targets for chimeric antigen receptor-based therapies in lymphoma.淋巴瘤中基于嵌合抗原受体疗法的新型多靶点
Front Oncol. 2024 Apr 22;14:1396395. doi: 10.3389/fonc.2024.1396395. eCollection 2024.
5
Anti-CD30 CAR T cells as consolidation after autologous haematopoietic stem-cell transplantation in patients with high-risk CD30 lymphoma: a phase 1 study.抗CD30嵌合抗原受体T细胞作为高危CD30淋巴瘤患者自体造血干细胞移植后的巩固治疗：一项1期研究
Lancet Haematol. 2024 May;11(5):e358-e367. doi: 10.1016/S2352-3026(24)00064-4. Epub 2024 Mar 28.
6
Chimeric Antigen Receptor-T Cell Therapy for Lymphoma: New Settings and Future Directions.嵌合抗原受体T细胞疗法治疗淋巴瘤：新的应用场景与未来方向
Cancers (Basel). 2023 Dec 21;16(1):46. doi: 10.3390/cancers16010046.
7
Few and far between: clinical management of rare extranodal subtypes of mature T-cell and NK-cell lymphomas.寥寥无几：罕见结外成熟 T 细胞和 NK 细胞淋巴瘤的临床处理方法。
Haematologica. 2023 Dec 1;108(12):3244-3260. doi: 10.3324/haematol.2023.282717.
8
Refractory celiac disease and its mimickers: a review on pathogenesis, clinical-pathological features and therapeutic challenges.难治性乳糜泻及其模仿者：关于发病机制、临床病理特征和治疗挑战的综述
Front Oncol. 2023 Nov 7;13:1273305. doi: 10.3389/fonc.2023.1273305. eCollection 2023.
9
Transient responses and significant toxicities of anti-CD30 CAR T cells for CD30+ lymphomas: results of a phase 1 trial.抗 CD30 CAR T 细胞治疗 CD30+淋巴瘤的一过性反应和显著毒性：一项 1 期试验结果。
Blood Adv. 2024 Feb 13;8(3):802-814. doi: 10.1182/bloodadvances.2023011470.
10
Education and Empowering Special Forces to Eradicate Secret Defectors: Immune System-Based Treatment Approaches for Mature T- and NK-Cell Malignancies.教育与赋能特种部队以根除秘密叛逃者：基于免疫系统的成熟T细胞和NK细胞恶性肿瘤治疗方法
Cancers (Basel). 2023 Apr 28;15(9):2532. doi: 10.3390/cancers15092532.
本文引用的文献
1
Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma.抗 CD30 CAR-T 细胞疗法在复发/难治性霍奇金淋巴瘤中的应用。
J Clin Oncol. 2020 Nov 10;38(32):3794-3804. doi: 10.1200/JCO.20.01342. Epub 2020 Jul 23.
2
Targeting T-cell malignancies using anti-CD4 CAR NK-92 cells.使用抗CD4嵌合抗原受体自然杀伤细胞92（CAR NK-92）细胞靶向T细胞恶性肿瘤。
Oncotarget. 2017 Nov 22;8(68):112783-112796. doi: 10.18632/oncotarget.22626. eCollection 2017 Dec 22.
3
Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes.CD30特异性嵌合抗原受体重定向淋巴细胞后的临床和免疫反应。
J Clin Invest. 2017 Sep 1;127(9):3462-3471. doi: 10.1172/JCI94306. Epub 2017 Aug 14.
4
CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies.表达用于治疗T细胞恶性肿瘤的CD7特异性嵌合抗原受体（CAR）的CD7编辑T细胞。
Blood. 2017 Jul 20;130(3):285-296. doi: 10.1182/blood-2017-01-761320. Epub 2017 May 24.
5
Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial.表达 CD30 嵌合抗原受体的自体 T 细胞治疗复发或难治性霍奇金淋巴瘤的开放性 I 期临床试验。
Clin Cancer Res. 2017 Mar 1;23(5):1156-1166. doi: 10.1158/1078-0432.CCR-16-1365. Epub 2016 Aug 31.
6
Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels.免疫组织化学作为评估外周 T 细胞淋巴瘤 CD30 表达的有价值工具：与 mRNA 水平高度相关。
Blood. 2014 Nov 6;124(19):2983-6. doi: 10.1182/blood-2014-07-584953. Epub 2014 Sep 15.
7
Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.霍奇金淋巴瘤和非霍奇金淋巴瘤初始评估、分期及反应评估的建议：卢加诺分类
J Clin Oncol. 2014 Sep 20;32(27):3059-68. doi: 10.1200/JCO.2013.54.8800.
8
Current concepts in the diagnosis and management of cytokine release syndrome.细胞因子释放综合征的诊断和治疗的当前概念。
Blood. 2014 Jul 10;124(2):188-95. doi: 10.1182/blood-2014-05-552729. Epub 2014 May 29.
9
Brentuximab in the treatment of CD30-positive enteropathy-associated T-cell lymphoma.本妥昔单抗治疗 CD30 阳性肠病相关性 T 细胞淋巴瘤。
J Natl Compr Canc Netw. 2013 Feb 1;11(2):137-40; quiz 140. doi: 10.6004/jnccn.2013.0021.
10
Autologous stem cell transplantation for enteropathy-associated T-cell lymphoma: a retrospective study by the EBMT.肠病相关 T 细胞淋巴瘤的自体干细胞移植：EBMT 的回顾性研究。
Blood. 2013 Mar 28;121(13):2529-32. doi: 10.1182/blood-2012-11-466839. Epub 2013 Jan 29.
Zotero 插件